| Literature DB >> 32651581 |
Seth J Zost1, Pavlo Gilchuk1, Rita E Chen2,3, James Brett Case3, Joseph X Reidy1, Andrew Trivette1, Rachel S Nargi1, Rachel E Sutton1, Naveenchandra Suryadevara1, Elaine C Chen4, Elad Binshtein1, Swathi Shrihari3, Mario Ostrowski5, Helen Y Chu6, Jonathan E Didier7, Keith W MacRenaris7, Taylor Jones1, Samuel Day1, Luke Myers1, F Eun-Hyung Lee8, Doan C Nguyen8, Ignacio Sanz8, David R Martinez9, Paul W Rothlauf10,11, Louis-Marie Bloyet11, Sean P J Whelan10,11, Ralph S Baric9, Larissa B Thackray3, Michael S Diamond2,3,11,12, Robert H Carnahan13,14, James E Crowe15,16,17.
Abstract
Antibodies are a principal determinant of immunity for most RNA viruses and have promise to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 has caused a global pandemic with millions of infections and hundreds of thousands of deaths to date1,2. In response, we used a rapid antibody discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-2 spike (S) protein. We stratify these mAbs into five major classes on the basis of their reactivity to subdomains of S protein as well as their cross-reactivity to SARS-CoV. Many of these mAbs inhibit infection of authentic SARS-CoV-2 virus, with most neutralizing mAbs recognizing the receptor-binding domain (RBD) of S. This work defines sites of vulnerability on SARS-CoV-2 S and demonstrates the speed and robustness of advanced antibody discovery platforms.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32651581 PMCID： PMC8194108 DOI： 10.1038/s41591-020-0998-x
Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 87.241